The management of schizophrenia is generally a long-term process with neuroleptics representing the cornerstone of treatment. Although not without their own limitations, depot neuroleptics offer an important alternative to oral agents, and they should be routinely considered as an option in any long-term treatment planning. The present article reviews depot neuroleptics, and focuses particularly on clinical considerations pertaining to their use.
References
1.
DenikerP.The neuroleptics: a historical survey.Acta Psychiatr Scand1990; 82(358 Suppl): 83–87.
2.
CurryS.H.Commentary: the strategy and value of neuroleptic drug monitoring.J Clin Psychopharmacol1985; 5: 263–267.
3.
Van PuttenT.Why do schizophrenics refuse to take their drugs?Arch Gen Psychiatry1974; 3: 67–72.
4.
CooriganP.W., LibermanR.P., EngelJ.D.From noncompliance to collaboration in the treatment of schizophrenia.Hosp Commun Psychiatry1990; 41: 1203–1211.
5.
JohnsonD.A.W., FreemanH.L.Drug defaulting by patients on long-acting phenothiazines.Psychol Med1973; 3: 115–119.
6.
FalloonI., WattD.C., ShepherdM.A.A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia.Psychol Med1976; 8; 59–70.
7.
QuitkinF., RifkinA., KaneJ.M.Long-acting oral drugs versus injectable antipsychotic drugs in schizophrenics. A one-year double-blind comparison in multiple episode schizophrenics.Arch Gen Psychiatry1978; 35: 889–892.
8.
CursonD.A.I., BarnesT.R.E., BamberR.W.K.Long-term depot maintenance of chronic schizophrenic outpatients: the seven year follow-up of the MRC fluphenazine/placebo trial.Br J Psychiatry1985; 46: 464–480.
9.
JohnsonD.A.W., WrightN.Drug prescribing to schizophrenic outpatients on depot injections: repeat surveys over eighteen years.Br J Psychiatry1990; 156: 827–834.
10.
DavisJ.M., AndriukaitisS.The natural course of schizophrenia and effective maintenance drug treatment.J Clin Psychopharmacol1986; 6: 2S–10S.
ConleyR.R., JohnsonD.A.W.British versus United States usage of depot neuroleptics.Relapse1991; 1: 1–2.
13.
JohnsonD.A.W.Depot therapy - advantages, disadvantages and issues of dose. In: JohnsonD.A.W., CarneyM.P.W., DenckerS.J., eds. Depot antipsychotics in chronic schizophrenia: proceedings of a symposium.Amsterdam: Excerpta Medica,1991.
14.
JannM.W., EreshefskyL., SakladS.R.Clinical pharmacokinetics of the depot antipsychotics.Clin Pharmacokinet1985; 10: 315–333.
15.
Van PuttenT., MarderS.R., WirshingW.C.Neuroleptic plasma levels.Schizophr Bull1991; 17: 197–216.
16.
BarnesT.R.E.Depot antipsychotic drugs and prevention of psychotic relapse.Clin Neuropharmacol1991; 14: S1–S6.
17.
YadalamD.G., SimpsonG.M.Changing from oral to depot fluphenazine.J Clin Psychiatry1988; 49: 346–348.
18.
MarderS.R., HubbardJ.W., Van PuttenT.Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.Psychopharmacology1989; 98: 433–439.
19.
GardosG.Are antipsychotics interchangeable?J Nerv Ment Dis1974; 159: 343–348.
20.
RowlandM., TozerT.N.Clinical pharmacokinetics: concepts and applications.Philadelphia: Lea and Febiger,1989.
21.
WilesD.H., McCreadieR.G., WhiteheadA.Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.Psychopharmacology1990; 101: 274–281.
22.
EreshefskyL., SakladS.R., JannM.W.Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.J Clin Psychiatry1984; 45: 50–59.
23.
SimpsonG.M.A brief history of depot neuroleptics.J Clin Psychiatry1984; 45: 3–4.
DreyfussJ., ShawJ.M., RossR.R.Fluphenazine enanthate and fluphenazine decanoate: intramuscular injections and esterification as requirements for slow-release characteristics in dogs.J Pharm Sci1976; 63: 1310–1315.
26.
JorgensenT., OveroK.F., BogesoK.P.Pharmacokinetic studies on clopenthixol decanoate: a comparison with clopenthixol in dogs and cats.Acta Pharmacol Toxicol1977; 41: 103–120.
27.
JorgensenA., GottfriesC.G.Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labelled compounds.Psychopharmacology1972; 27: 1–10.
28.
KnudsenP., HansenL.B., LarsenN-E.Pharmacokinetic implications of different oil vehicles used in depot neuroleptic treatment.Acta Psychiatr Scand1985; 72(322 Suppl): 2–10.
29.
WistedtB., WilesD., KolakowskaT.Slow decline in plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics.Lancet1981; i: 1163.
30.
WistedtB., JorgensenA., WilesD.A depot neuroleptic withdrawal study. Plasma concentrations of fluphenazine and flupenthixol and relapse frequency.Psychopharmacology1982; 78: 301–304.
31.
GitlinM.J., MidhaK.K., FogelsonD.Persistence of fluphenazine in plasma after decanoate withdrawal.J Clin Psychopharmacol1988; 8: 53–56.
32.
StauningJ.A., KirkL., JorgensenA.Comparison of serum levels after intramuscular injections of 2% and 10% eis (z)-flupenthixol decanoate in viscoleo to schizophrenic patients.Psychopharmacology1979; 65: 69–72.
33.
ReyntjensA.J.M., HeykantsJ.J.P., WoestenborghsR.J.H.Pharmacokinetics of haloperidol decanoate: a 2-year follow-up.Int Pharmacopsychiatry1982; 17: 238–246.
34.
SuyE., WoestenborghsR., HeykantsJ.Bioavailability and clinical effect of two different concentrations of haloperidol decanoate.Curr Ther Res1982; 31: 982–991.
35.
DiamondR.J.Enhancing medication use in schizophrenic patients.J Clin Psychiatry1983; 44: 253–261.
36.
JohnsonD.A.W., KaneJ.M., SimpsonG.I.The use of depot neuroleptics: clinical experience in the United States and the United Kingdom. Presented at International Conferences on Depot and Oral Neuroleptics, Los Angeles, California, May 1984.
37.
BourinM., VenisseJ.L., LecuyerF.Résultats d'une enquête sur l'utilisation en psychiatrie des neuroleptiques à action prolongée.Encéphale1990; 16: 363–369.
38.
RemingtonG.J., PrendergastP., Bezchlibnyk-ButlerK.Z.Dosaging patterns in schizophrenia with depot, oral and combined neuroleptic therapy.Can J Psychiatry1993; 38(3): 159–161.
39.
RemingtonG.J.A Canadian perspective on the use of depot neuroleptics.Relapse1992; 2: 3–4.
40.
WesbyR., EarleJ., BullmoreE.Community care of patients receiving antipsychotic medication by depot injection.Br J Gen Pract1993; 43: 83–84.
41.
GloverG., MalcolmG.The prevalence of depot neuroleptic treatment among West Indians and Asians in the London borough of Newham.Soc Psychiatry Psychiatr Epidemiol1988; 23: 281–284.
42.
PriceN., GlazerW., MorgensternH.Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatientsAm J Psychiatry1985; 142: 1491–1492.
43.
CournosF., McKinnonK., StanleyB.Outcome of involuntary medication in a state hospital system.Am J Psychiatry1991; 148: 489–494.
44.
CarpenterW.T., KeithS.J.Integrating treatments in schizophrenia.Psychiatr Clin North Am1996; 9: 153–164.
45.
KaneJ.M.Treatment of schizophrenia.Schizophr Bull1987; 13: 133–156.
46.
RemingtonG., AdamsM.Depot neuroleptics. In: AncillR.J., HollidayS., HigenbottamJ., eds. Schizophrenia: exploring the spectrum of psychosis.Chichester: John Wiley & Sons,1954.
47.
McConnellE.A.The subtle art of really good injections.RN1982; February: 25–34.
48.
MoundB., FlanaganE., O'KeefeG.Self-injection of neuroleptics.Can Nurse1990; June: 31–32.
49.
GlazerW.M., MaynardC., BerkmanC.S.Injection site leakage of depot neuroleptics: intramuscular versus subcutaneous injection.J Clin Psychiatry1987; 48: 237–239.
50.
BelangerM-C, ChouinardG.Technique for injecting long-acting neuroleptics.Br J Psychiatry1982; 141: 316.
51.
MiddlemissM.A., BeeberL.S.(1989) Issues in the use of depot antipsychotics.J Psychosoc Nurs Ment Health Serv1989; 27: 36–37.
52.
AydF.J.Jr.The depot fluphenazines: a reappraisal after 10 years' clinical experience.Am J Psychiatry1975; 132: 491–500.
53.
De CuyperH., BollenJ., van PraagH.M.Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration.Br J Psychiatry1986; 148: 560–566.
54.
EreshefskyL., SakladS.R., Tran-JohnsonT.Kinetics and clinical evaluation of haloperidol decanoate loading dose regimen.Psychopharmacol Bull1990; 26: 108–114.
55.
WeidenP., SchoolerN.R., SevereJ.B.Stabilization and depot neuroleptic dosages.Psychopharmacol Bull1993; 29: 269–275.
56.
JohnsonD.A.W., LudlowJ.M., StreetK.Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised outpatients with schizophrenia.Br J Psychiatry1987; 151: 634–638.
57.
KaneJ.M., RifkinA., WoernerM.High-dose versus low-dose strategies in the treatment of schizophrenia.Psychopharmacol Bull1985; 21: 533–537.
58.
KaneJ.M.Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.J Clin Psychopharmacol1986; 6: 20S–23S.
59.
KaneJ.M., WoernerM., SarantakosS.Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens.J Clin Psychiatry1986; 47(5 Suppl): 30–33.
HogartyG.E.Depot neuroleptics: the relevance of psychosocial factors - a United States perspective.J Clin Psychiatry1984; 45: 36–42.
62.
KaneJ.M., RifkinA., WoernerM.Low-dose neuroleptic treatment of outpatient schizophrenics 1. Preliminary results for relapse rates.Arch Gen Psychiatry1983; 40: 893–896.
63.
MarderS.R., Van PuttenT., MintzJ.Costs and benefits of two doses of fluphenazine.Arch Gen Psychiatry1984; 41: 1025–1029.
64.
BeresfordR., WardA.Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis.Drugs1987; 33: 31–49.
65.
MarderS.R., HawesE.M., Van PuttenT.Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.Psychopharmacology1986; 88; 480–483.
66.
AydF.J.Jr.Depot pipotiazine palmitate: thirteen years later.Int Drug Ther Newsletter1983; 18: 5–8.
67.
KroghM.E., ed. Compendium of pharmaceuticals and specialities.Ottawa: Canadian Pharmaceutical Association,1994.
68.
MasonA.S., GranacherR.P.Basic principles of rapid neuroleptization.Dis Nerv Syst1976; 37: 547–551.
69.
StimmelG.Schizophrenia. In: CoyleJ.T., EnnaS.J., eds. Clinical pharmacy and therapeutics.Baltimore MD: Williams and Wilkins,1985.
70.
EreshefskyL., RichardsA.L., GrotheD.R.Pharmacokinetic and clinical evaluation of the conversion from oral to depot fluphenazine. Unpublished data, 1985.
71.
DeberdtR., ElensP., BerghmansW.Intramuscular haloperidol decanoate for neuroleptic maintenance therapy, efficacy, dosage schedule and plasma levels.Acta Psychiatr Scand1980; 62: 356–363.
72.
De BuckR.P., ZelaschiN., GillesC.Theoretical and practical importance of plasma levels of haloperidol. Correlations with clinical and computerized EEG data.Prog Neuropsychopharmacol1981; 5: 499–502.
73.
ZuardiA.W., GiampetroA.C., GrassiE.C.Double-blind comparison between two forms of haloperidol: an oral preparation and a new decanoate in the maintenance of schizophrenic inpatients.Curr Ther Res1983; 34: 253–261.
74.
Suarez RichardsM., Actis DatoA.C., ZelaschiN.M.Monthly haloperidol decanoate substitutes for daily neuroleptics in psychotic inpatients.Curr Ther Res1982; 32: 586–589.
75.
ViukariM., SaloH., LamminisivuU.Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients.Acta Psychiatr Scand1982; 65: 301–308.
76.
NairN.P.V., Suranyi-CadotteB., SchwartzG.A clinical trial comparing intramuscular haloperidol and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.J Clin Psychopharmacol1986; 6: 30S–37S.
77.
BechelliL.P.C., Navas-FilhoF.Short-term double blind trial of pipotiazine palmitate and haloperidol in the acute phase of schizophrenia.Encéphale1986; 12: 121–125.
HebenstreitG.F.Clinical experience with zuclopenthixol acetate and co-injection of zuclopenthixol acetate and zuclopenthixol decanoate. In: StefanisC.N., ed. Psychiatry -a world perspective (volume three).Amsterdam: Elsevier,1990.
80.
KaziH.A.G.An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance treatment of schizophrenia.Pharmacotherapeutica1986; 4: 555–560.
81.
WistedtB., KoskinenT., ThelanderS.Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study.Acta Psychiatr Scand1991; 84: 14–16.
82.
MarderS.R.Depot neuroleptics: side effects and safety.J Clin Psychopharmacol1986; 6: 24S–29S.
83.
TegelerJ., LehmannE., WeiherA.Safety of long-term neuroleptanxiolysis with fluspirilene 1.5 mg per week.Pharmacopsychiatry1990; 23: 259–264.
84.
MiserdaR., BuranE., SchilkrutR.Long-term treatment of chronic schizophrenic patients with haloperidol decanoate. Unpublished data on file, Janssen Pharmaceutica, 1983.
85.
GrovesJ.E., MandelM.R.The long-acting phenothiazines.Arch Gen Psychiatry1975; 32: 893–900.
86.
HamannG.L., EganT.M., WellsB.G.Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/ml.J Clin Psychiatry1990; 51: 502–504.
87.
HamannG.L., WellsB.G.Drs. Hamman and Wells reply.J Clin Psychiatry1992; 53: 415–416.
88.
ReinkeM., WiesertK.N.High incidence of haloperidol decanoate injection site reactions.J Clin Psychiatry1992; 53: 415.
UNIVRES.Directory of federally supported research in universities. Canadian Institute for Scientific and Technical Information.Ottawa: National Research Council of Canada,1987.
91.
Canadian Centre for Health Information.Ottawa ON: Statistics Canada, Health Reports, 1991 (Suppl 1 and 3).
92.
Health Canada Statistics.Ottawa ON, 1993.
93.
RevickiD.A., LuceB.R., WeschlerJ.M.Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients.Hosp Commun Psychiatry1990; 4: 850–854.
94.
HonigfeldG., PatinG.A two-year clinical and economic follow-up of patients on clozapine.Hosp Commun Psychiatry1990; 41: 882–885.
95.
RemillardA.J., JohnsonJ.A.A pharmacoeconomic evaluation of clozapine in one patient.Can J Hosp Pharm1993; 46: 115–119.
96.
MeltzerH.Y., ColaP., WayL.Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.Am J Psychiatry1993; 150: 1630–1638.
